Growth Rate Decay Assumptions in DCF Valuation: Designing Terminal Value Models for High-Growth Firms

The SFC’s 2024 consultation on the regulation of sponsors and the HKEX’s updated guidance on listing suitability for high-growth, pre-revenue biotech and tech firms under Chapter 18C have sharpened the scrutiny on long-term financial projections in IPO prospectuses. In the first half of 2025, the HKEX rejected three listing applications where the sponsor’s implied terminal growth rates exceeded 5% for firms with no clear path to market leadership, citing a lack of reasonable basis under Listing Rule 11.06. This regulatory focus directly challenges the DCF practitioner: for a firm growing at 30% CAGR today, how does one defensibly model the transition to a 3% terminal rate without injecting subjective optimism? The answer lies not in a single discount rate adjustment, but in a structured decay function that maps growth to observable competitive fade. This article builds a quantitative framework for designing terminal value models that survive regulatory scrutiny and audit review, using Hong Kong-listed precedents and SFC enforcement cases as boundary conditions.

The Terminal Value Trap in High-Growth Listings

The terminal value in a DCF model for a high-growth firm frequently accounts for 60-80% of total enterprise value, according to a 2023 study by the CFA Institute. For Hong Kong-listed growth stocks, this proportion is even higher: a review of 15 Chapter 18C applicants between 2023 and 2025 showed an average terminal value contribution of 74% of total equity value in sponsor valuation reports. The problem is structural: when a firm grows at 25% for five years, even a modest 4% terminal growth rate can produce a terminal value that is 8-10x the sum of the discrete projection period cash flows.

The Regulatory Boundary: HKEX’s Implied Ceiling on Terminal Growth

HKEX Listing Decision HKEX-LD132-2023 explicitly warned sponsors against using terminal growth rates above the long-term nominal GDP growth of the firm’s primary operating economy without a documented competitive advantage that supports sustained above-market returns. For a PRC-domiciled issuer, this effectively caps terminal growth at approximately 3.5-4.0%, based on the IMF’s April 2025 World Economic Outlook projection for China’s nominal GDP growth of 4.2% through 2029. The SFC’s 2024 Sponsor Thematic Inspection Report identified three cases where sponsors used terminal growth rates of 5-6% for consumer tech firms, which the SFC deemed “unsupported by any market share or pricing power analysis.”

The Mathematics of Fade: Why Linear Decay Fails

A common error in practitioner models is the use of a linear decay function—reducing the growth rate by a fixed percentage point each year until reaching the terminal rate. This approach fails for two reasons. First, competitive fade is non-linear: a firm growing at 30% experiences a sharper deceleration in years 3-5 as market saturation and competitor entry take effect, followed by a slower taper. Second, linear decay produces an artificially high average growth rate across the fade period, inflating the terminal value by 12-18% compared to a logistic decay function, as demonstrated by Damodaran’s 2022 dataset on US and HK-listed firms.

Designing a Defensible Decay Function

A robust terminal value model for a high-growth firm requires a decay function with three properties: (1) it converges to the terminal rate within a defined horizon, (2) it reflects the firm’s specific competitive moat duration, and (3) it produces a terminal value that is no more than 70% of total enterprise value—a threshold the HKEX has informally applied in sponsor reviews since 2024.

The Logistic Decay Model

The logistic decay function expresses the growth rate at time t as: g(t) = g_terminal + (g_0 - g_terminal) / (1 + e^(k * (t - t_half))), where g_0 is the initial high-growth rate, g_terminal is the long-term sustainable rate, k is the decay speed parameter, and t_half is the year at which growth has decayed halfway to terminal. For a Hong Kong-listed SaaS firm with g_0 = 35% and g_terminal = 3.5%, setting t_half at year 4 and k at 0.8 produces a growth rate of 19.2% in year 2, 9.1% in year 4, and 4.8% in year 6—a pattern consistent with the actual revenue trajectories of HKEX-listed Tongcheng-Elong (0780.HK) and Weimob (2013.HK) during their post-IPO deceleration phases.

Calibrating Decay Speed to Competitive Moat Duration

The decay speed parameter k must be calibrated to the firm’s competitive moat duration, which can be estimated using the ratio of gross margin to sales and marketing expense. For firms with gross margins above 70% and sales and marketing below 25% of revenue—indicating pricing power and customer retention—k should be set between 0.5 and 0.7, implying a slower fade over 8-10 years. For firms with gross margins below 50% or sales and marketing above 40% of revenue, k should be 0.9 to 1.2, implying a rapid fade within 4-6 years. This framework was applied in the successful listing of QuantumPharm (2228.HK) in 2024, where the sponsor used a k of 0.6 based on the firm’s 78% gross margin and 18% sales and marketing ratio.

Stress Testing Against Regulatory and Market Scenarios

A terminal value model that passes internal review may still fail regulatory scrutiny if it does not withstand scenario testing. The SFC’s 2023 Code of Conduct for Sponsor and Placing Agents requires that all financial projections in a prospectus be “reasonably based on assumptions that are not overly optimistic.” This translates into a requirement that the terminal value must remain within 80% of the base case under at least two of three stress scenarios.

Scenario 1: Terminal Growth Rate Compression

Under the SFC’s guidance, sponsors must test a terminal growth rate 100 bps below the base case. For a firm with a base terminal growth of 3.5%, this means testing at 2.5%. The impact on terminal value is a reduction of 22-28%, depending on the weighted average cost of capital (WACC). If this reduction pushes the terminal value below 50% of total enterprise value, the model is likely over-reliant on terminal assumptions and should be restructured with a longer discrete projection period.

Scenario 2: WACC Expansion in a Rising Rate Environment

With the HKMA’s Base Rate at 4.75% as of July 2025, and the US Federal Reserve holding at 5.25-5.50%, the cost of equity for Hong Kong-listed growth firms has risen to 12-15%, according to Bloomberg’s WACC composite for the Hang Seng Tech Index. A stress scenario increasing WACC by 150 bps—to, say, 14.5% from 13.0%—reduces terminal value by 30-35%. The model must demonstrate that even at this higher WACC, the terminal value does not exceed 75% of total enterprise value.

Scenario 3: Revenue Half-Life Shortening

The most realistic stress for a high-growth firm is a faster-than-expected competitive fade. This is tested by reducing the decay half-life t_half by two years—for example, from year 4 to year 2. This scenario typically reduces the terminal value contribution by 15-20 percentage points. If the resulting terminal value still exceeds 70% of total enterprise value, the sponsor should extend the discrete projection period from 5 to 7 years, as was done in the listing of JD Logistics (2618.HK) in 2021.

Practical Implementation for Sponsor Valuation Reports

The design of a decay function is not merely an academic exercise—it directly affects the defensibility of a sponsor’s valuation opinion under SFC enforcement. In the 2024 enforcement case against a sponsor for the listing of a PRC e-commerce firm, the SFC cited the use of a “mechanically applied linear decay from 30% to 3% over five years without any firm-specific justification” as a factor in the sponsor’s failure to discharge its duty under paragraph 17 of the Code of Conduct.

Documentation Requirements

A defensible terminal value model must include a written memorandum documenting: (1) the source of the initial high-growth rate, cross-referenced to the prospectus financials; (2) the basis for the terminal growth rate, citing the HKEX’s implied ceiling and the relevant nominal GDP projection from the IMF or the Hong Kong Census and Statistics Department; (3) the competitive moat analysis supporting the decay speed parameter k, with reference to gross margin, sales and marketing ratio, and customer churn data; and (4) the results of all three stress scenarios, with a clear statement that the terminal value remains within the 70% threshold.

The Role of Independent Expert Reports

For firms with no direct comparable companies in Hong Kong—such as AI or biotech firms listing under Chapter 18C—the HKEX may require an independent expert report on the valuation methodology under Listing Rule 11.06. In such reports, the decay function must be justified by reference to the firm’s patent portfolio, regulatory approvals, or contracted revenue backlog. The 2024 listing of a gene therapy firm used a decay function with t_half set at year 6 and k at 0.5, justified by 12 patents with mean remaining life of 9.4 years and a contracted revenue backlog covering 3.2 years of projected revenue.

Actionable Takeaways

1. Set the terminal growth rate at or below the long-term nominal GDP growth of the firm’s primary operating economy, currently 3.5-4.0% for PRC-domiciled issuers per the IMF’s April 2025 World Economic Outlook, and document the source explicitly in the valuation memorandum.
2. Replace linear decay with a logistic decay function calibrated to the firm’s competitive moat duration, using gross margin and sales-to-marketing ratio as the primary inputs for the decay speed parameter k.
3. Ensure the terminal value does not exceed 70% of total enterprise value in the base case, and test this threshold under three stress scenarios: terminal growth compression of 100 bps, WACC expansion of 150 bps, and revenue half-life shortening by two years.
4. Document the decay function design in a standalone memorandum that cross-references the prospectus financials, the competitive moat analysis, and the stress test results, as required by paragraph 17 of the SFC’s Code of Conduct for Sponsor and Placing Agents.
5. For Chapter 18C applicants or firms with no direct comparables, engage an independent expert to validate the decay function against the firm’s patent portfolio or contracted revenue backlog, in line with HKEX Listing Rule 11.06.